Quantcast

Latest Glucagon Stories

2014-09-11 20:21:50

WASHINGTON, Sept. 11, 2014 /PRNewswire/ -- Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the Food and Drug Administration (FDA) has completed its meeting regarding the New Drug Application (NDA) for Saxenda(®), the intended brand name for liraglutide 3 mg, a once-daily human GLP-1 analogue for the treatment of obesity. Based on the data contained in the NDA for Saxenda(®), the FDA asked the panel members to discuss whether...

2014-06-16 08:27:42

Up to 2.25 percentage point reduction in HbA1c achieved after only 13 weeks of dosing CARLSBAD, Calif., June 16, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the final results from its Phase 2 study of ISIS-GCGR(Rx) in patients with type 2 diabetes uncontrolled on stable metformin therapy. In this study, patients in the per protocol population (PP) treated with ISIS-GCGR(Rx) in addition to metformin achieved absolute mean reduction in hemoglobin...

2014-06-14 12:20:48

CSO Dr. Peter Daddona to Share Data on Use of ZP-Glucagon Product Candidate in Healthy Volunteers FREMONT, Calif., June 14, 2014 /PRNewswire/ -- Zosano Pharma, Inc., a privately held biopharmaceutical company developing products based on its novel transdermal delivery technology, announced that Peter Daddona, Ph.D., Chief Scientific Officer and Executive Vice President, Research & Development, will present data today on its ZP-Glucagon product candidate at the 74(th) American...

2014-06-14 12:20:29

Data also showed liraglutide 3 mg improved blood glucose control compared to placebo at 56 weeks SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- Today, primary results from SCALE(TM) Diabetes, a phase 3a clinical trial of liraglutide 3 mg, an investigational once-daily glucagon-like peptide-1 (GLP-1) analogue for chronic weight management, were presented for the first time at the 74th Annual Scientific Sessions of the American Diabetes Association (ADA) in San Francisco,...

2014-05-19 08:28:38

FREMONT, Calif., May 19, 2014 /PRNewswire/ -- Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, announced that Dr. Peter Daddona, the company's Chief Scientific Officer and Executive Vice President, Research & Development, will present data today on its ZP-Glucagon product candidate at the 3(rd) International Conference on Microneedles, in Baltimore, Maryland. Dr. Daddona is an invited speaker...

2014-05-16 08:25:50

LAS VEGAS, May 16, 2014 /PRNewswire/ -- Results from the SCALE(TM) Obesity and Pre-diabetes phase 3a trial will be presented on May 16, 2014, for the first time at the 23rd Annual Congress of the American Association of Clinical Endocrinologists (AACE). Data showed that after 56 weeks of treatment, liraglutide 3 mg, in combination with diet and exercise, provided significantly greater weight loss of 8% from baseline compared to 2.6% with placebo (P<0.0001). This is the largest...

2014-05-14 08:29:48

Greater than 2 percentage point reduction in HbA1c achieved after only 13 weeks of dosing CARLSBAD, Calif., May 14, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today positive data from a Phase 2 study of ISIS-GCGR(Rx) in patients with type 2 diabetes uncontrolled on stable metformin therapy. In this study, patients in the per protocol efficacy population treated with ISIS-GCGR(Rx) achieved statistically significant reductions in measures of glucose...

3D Structure Of Key Drug Target For Diabetes Found
2013-07-18 08:27:10

Scripps Research Institute An international team led by scientists at The Scripps Research Institute (TSRI) has determined and analyzed the three-dimensional atomic structure of the human glucagon receptor. The receptor, found mainly on liver and kidney cells, helps regulate glucose levels in the bloodstream and is the target of potential therapeutic agents for type 2 diabetes. "Our data should change the current view of how drugs are designed with this and related receptors," said TSRI...


Latest Glucagon Reference Libraries

0_0d961f30bdfa64859d9b869b063ddcd2
2010-12-03 18:12:26

Insulin, a hormone, is used to regulate carbohydrate and fat metabolism in the body. Insulin causes cells to take up glucose from the blood and store it as glycogen in the liver and muscle. This hormone stops the body from using fat as an energy source by inhibiting the release of glucagons. Without insulin the body fails to take glucose into the bodies cells and in turns uses fat as an energy source. It also has several other anabolic effects throughout the body. Diabetes mellitus results...

More Articles (1 articles) »
Word of the Day
abrosia
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.